Lacking Revenue, Jenscare Scientific Hopes IPO Investors Take Heart in Its Potential
The maker of devices to treat structural heart disease hopes to have its first product approved in the second half of next year as it prepares to list in Hong…
RELATED ARTICLES
-
Huge Dental hopes Hong Kong smiles on its latest listing attempt
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Newborn Town reports blowout business, but investors fail to move in
9911.HK
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
- IPO pitch puts BrainAurora’s earnings under the microscope
-
Airdoc Tech enjoys healing properties of medical AI rally
2251.HK
